Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yuanzhao Cao has a total of 80 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Glycaemic variability underlies myocyte dysfunction and myocardial injury risk in diabetes

    by Yuanzhao Cao, Meredith A. Redd, Jennifer E. Outhwaite, Dalia Mizikovsky, Woo Jun Shim, Chen Fang, Courtney Vedelago, Clarissa Tan, Zhixuan Wu, Dara Daygon, et al.

    Heart disease is the leading cause of morbidity and mortality in individuals with diabetes, due largely to risks associated with ischaemic injuries such as myocardial infarction (MI). We use human population genetic data to demonstrate that classical cardiovascular disease risk biomarkers, including common measures of hyperglycaemia, do not fully account for the increased risk of post-MI mortality in patients with diabetes. This study therefore systematically evaluates glycaemic stress underpinning cardiovascular risk in diabetes. Here, we show using in vivo studies in adult male mice and in vitro models that glycaemic variability, rather than sustained hyperglycaemia alone, is a key risk factor for cardiomyocyte dysfunction and increased susceptibility to myocardial injury in diabetes. We further demonstrate that patient plasma assays can elucidate the predictive potential of glycaemic variability as a primary contributor to cardiomyocyte dysfunction and subclinical cardiac injury in diabetes. These findings provide preclinical models for mechanistic and drug discovery studies and inform strategies for managing cardiovascular outcomes in patients with diabetes.

  • Open Access

    Protocol-dependent cardiomyocyte states determine disease modelling capacity of human iPSCs

    by Sophie Shen, Clarissa Tan, Yuanzhao Cao, Chris Siu Yeung Chow, Dalia Mizikovsky, Janice Reid, Steve Dingwall, Andrew Prowse, Yuliangzi Sun, Zhixuan Wu, et al.

    Human induced pluripotent stem cell–derived cardiomyocytes (iPSC-CMs) are widely used to model cardiovascular disease, yet numerous differentiation protocols generate cardiomyocytes with heterogeneous molecular and functional properties, complicating experimental design. Here we systematically compare sixteen commonly used cardiomyocyte differentiation protocols and characterize their resulting cell states using single-nucleus RNA sequencing, functional phenotyping and computational integration with human genetic data. Despite similar cardiomyocyte yields, protocols produced distinct transcriptional programs, subtype compositions and physiological properties. By integrating protocol-specific gene expression signatures with genome-wide association studies of cardiovascular traits, we identify cardiomyocyte states enriched for genetic architectures underlying specific diseases. These analyses accurately predict protocols most suitable for modelling particular disease contexts, including electrophysiological defects associated with Brugada syndrome and metabolic vulnerability relevant to myocardial infarction. Our results demonstrate that differentiation protocols encode biologically distinct cardiomyocyte states with differential disease relevance and establish a framework for aligning stem-cell differentiation strategies with human complex trait genetics to guide model selection. This approach enables rational design of iPSC-based disease models and highlights how population-scale genetic data can inform experimental systems in stem cell biology.

  • Open Access

    Hierarchical control of cardiomyocyte maturation and ischaemia sensitivity by metabolic culture conditions

    by Yuanzhao Cao, Chris Siu Yeung Chow, Sumedha Negi, Woo Jun Shim, Sophie Shen, Chen Fang, Nathan J. Palpant

    Ischaemic heart disease remains the leading cause of mortality worldwide, yet no therapies prevent cardiomyocyte death during acute ischaemia–reperfusion injury (IRI). Human induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs) provide a platform for modelling cardiac injury, but their immature phenotype limits the physiological fidelity of in vitro models. Here, we systematically evaluated how experimental variables used during preparation of hiPSC-CM endpoint assays influence cardiomyocyte maturation and susceptibility to IRI. Integrating literature mining, molecular profiling, statistical genetics, and functional assays, we examined the effects of replating conditions, backbone media, metabolic substrates, and signalling modulators. We define the relationship between culture conditions and metabolic supplements in determining contractile maturation and sensitivity to IRI. Notably, we show that metabolic composition of the backbone medium establishes the baseline maturation state and determines responsiveness to additional maturation cues. These findings identify metabolic environment as a dominant regulator of injury susceptibility and provide a framework for improving the physiological fidelity of hiPSC-CM models of cardiac ischaemia.

  • Open Access

    Glycaemic variability underlies myocyte dysfunction and myocardial injury risk in diabetes

    by Nathan Palpant, Yuanzhao Cao, Meredith Redd, Jennifer Outhwaite, Dalia Mizikovsky, Woo Jun Shim, Chen Fang, Zhixuan Wu, Venea Dara Daygon, Terra Stark, et al.

    Heart disease is the leading cause of morbidity and mortality in individuals with diabetes, due largely to risks associated with ischaemic injuries such as myocardial infarction (MI). We use human population genetic data to demonstrate that current biomarkers of hyperglycaemia do not account for risk of post-MI mortality in diabetes patients. This study therefore systematically evaluates glycaemic stress underpinning cardiovascular risk in diabetes. Using in vivo and in vitro models, we demonstrate that glycaemic variability rather than hyperglycaemia alone is a dominant risk factor for heart muscle dysfunction and myocardial injury sensitivity in diabetes. These findings provide new preclinical models for mechanistic and drug discovery studies and inform strategies for managing cardiovascular outcomes in patients with diabetes.

  • Open Access

    Glycaemic variability underlies myocyte dysfunction and myocardial injury risk in diabetes

    by Yuanzhao Cao, Meredith A. Redd, Jennifer E. Outhwaite, Dalia Mizikovsky, Woo Jun Shim, Chen Fang, Zhixuan Wu, Dara Daygon, Terra Stark, Robin Palfreyman, et al.

    SUMMARY: Heart disease is the leading cause of morbidity and mortality in individuals with diabetes, due largely to risks associated with ischaemic injuries such as myocardial infarction (MI). We use human population genetic data to demonstrate that current biomarkers of hyperglycaemia do not account for risk of post-MI mortality in diabetes patients. This study therefore systematically evaluates glycaemic stress underpinning cardiovascular risk in diabetes. Using in vivo and in vitro models, we demonstrate that glycaemic variability rather than hyperglycaemia alone is a dominant risk factor for heart muscle dysfunction and myocardial injury sensitivity in diabetes. These findings provide new preclinical models for mechanistic and drug discovery studies and inform strategies for managing cardiovascular outcomes in patients with diabetes.

  • Open Access

    High-content fluorescence bioassay investigates pore formation, ion channel modulation and cell membrane lysis induced by venoms

    by Simon Kramer, Charan Kotapati, Yuanzhao Cao, Bryan G. Fry, Nathan J. Palpant, Glenn F. King, Fernanda C. Cardoso


  • Open Access

    High-content fluorescence bioassay to investigate pore formation, ion channel modulation and cell membrane lysis induced by venoms

    by Simon Kramer, Charan Kotapati, Yuanzhao Cao, Bryan G Fry, Nathan J Palpant, Glenn F King, Fernanda C Cardoso

    Venoms comprise highly evolved bioactive molecules modulating ion channels, receptors, coagulation factors, and the cellular membrane. This array of targets and bioactivity requires high-content bioassays to aid the development of novel envenomation treatments and biotechnological and pharmacological agents. To address this gap in venom’s research, we developed a fluorescence-based high-throughput and high-content cellular assay to simultaneously identify common cellular activities produced by venoms: membrane lysis, pore-formation, and ion channel modulation. By combining intracellular calcium with extracellular nucleic acid measurements, we distinguished these venom mechanisms using one cellular assay. We applied our high-content bioassay in three cell types exposed to venom components representing lytic, ion pore-forming or ion channel modulator toxins. Beyond the distinct profiles produced by these three types of action mechanisms, we found that the pore-forming latrotoxin α-Lt1a prefers human neuroblastoma to kidney cells and cardiomyocytes, while the lytic bee peptide melittin is not selective. Furthermore, evaluation of snake venoms showed that Elapid species induced rapid membrane lysis, while Viper species showed variable to no activity on neuroblastoma cells. These findings demonstrate that our high-content bioassay distinguish clades and interspecific traits and capture the clinical observations at venom level and is capable of differentiate ion pore-forming from membrane lysis and ion channel modulation. We hope our research will accelerate the understanding of venom biology and the diversity of toxins inducing cytotoxic, cardiotoxic and neurotoxic effects and assist in identifying venom components whose properties could benefit humankind.